The fact that biologic drugs are typically infused or injected poses numerous challenges, including discomfort for patients, instability under some storage conditions, and the generation of needle waste. Researchers have long sought a way to deliver biologics orally, and some teams have even reported progress toward the goal of delivering monoclonal antibodies in coated tablet forms. Now, researchers have reported in Nature Medicine that a luminal unfolding microneedle injector could be a feasible delivery device for biologic drugs like insulin.
The fact that biologic drugs are typically infused or injected poses numerous challenges, including discomfort for patients, instability under some storage conditions, and the generation of needle waste. Researchers have long sought a way to deliver biologics orally, and some teams have even reported progress toward the goal of delivering monoclonal antibodies in coated tablet forms. Now, researchers have reported in Nature Medicine that a luminal unfolding microneedle injector could be a feasible delivery device for delivering drugs like insulin.
The researchers, in a study funded by Novo Nordisk and the National Institutes of Health, developed a capsule that can carry insulin—and potentially other biologics—into the small intestine, where the capsule breaks down to reveal dissolvable microneedles on 3 folded arms. These needles attach to the intestinal wall and release the drug.
To allow the capsule to reach the small intestine, the researchers coated it with a polymer that can withstand stomach acidity until it reaches a pH of approximately 6.
Each of the arms, which are designed to break apart in order to reduce the risk of intestinal blockage, is covered with patches of 1 mm microneedles that are able to penetrate the topmost layer of the small intestine before they release the drug and dissolve.
In ex vivo human studies and in vivo swine studies, the capsule was demonstrated to load a comparable amount of insulin into test subjects as an injection would, allowing for fast uptake into the bloodstream; in the insulin tests, when the capsule was activated, the injector provided faster pharmacokinetic uptake than a subcutaneous injection over a 4-hour period.
In swine, no blockages formed in the intestine, and the capsule’s arms were safely excreted.
"We are really pleased with the latest results of the new oral delivery device our lab members have developed with our collaborators, and we look forward to hopefully seeing it help people with diabetes and others in the future," said Robert Langer, ScD, the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) and a member of the Koch Institute for Integrative Cancer Research, in a statement.
Giovanni Traverso, PhD, assistant professor in MIT's Department of Mechanical Engineering and gastroenterologist at Brigham and Women's Hospital, added that "We can deliver insulin, but we see applications for many other therapeutics and possibly vaccines," Traverso says. "We're working very closely with our collaborators to identify the next steps and applications where we can have the greatest impact."
Reference
Abramson A, Caffarel-Salvador E, Soares V, et al. A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat Med. 2019;25:1512-1518. doi: 10.1038/s41591-019-0598-9.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
How Streamlining Development Can Save the US Biosimilar Industry
August 20th 2023On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.
BioRationality: FDA Launches a New Opportunity to Remove Redundant Trials of Biosimilars
November 6th 2023The FDA introduced a plan to improve clinical trials, including a provision to possibly eliminate clinical efficacy testing for biologic products, which evidence has suggested may not be necessary, according to Sarfaraz K. Niazi, PhD.